Ovarian Cancer | Clinical

FDA Grants Priority Review to Injectable Pafolacianine Sodium to Identify Ovarian Cancer During Surgery

March 04, 2021

The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.

FDA Grants Fast Track Designation to GEN-1 for Advanced Ovarian Cancer

February 23, 2021

A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.

Historical and Current Data Inform the Ovarian Treatment Landscape for Practicing Oncologists

February 21, 2021

Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.

Combining Bevacizumab “Additive” But Not “Synergistic” With Olaparib, According to Moore

February 17, 2021

During a Targeted Oncology Case-Based Peer Perspective event, Kathleen Moore, MD, discussed the combination of bevacizumab and olaparib as treatment of ovarian cancer.

Ovarian Cancer Benefits From Molecular Testing for Appropriate Therapy Designation

January 02, 2021

During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.

Discussing Therapies Currently Available in High-Grade Epithelial Ovarian Cancer

December 25, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.

Exploring First-line Bevacizumab in Ovarian Cancer

December 24, 2020

Thomas C. Krivak, MD, interpreted the results clinical trials of bevacizumab as treatment of patients with ovarian cancer to determine the optimal treatment strategy for a 69-year-old patient.

Rucaparib Improves PFS in Patent With BRCA Mutation-Positive Relapsed Ovarian Cancer

December 21, 2020

Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.

Olaparib Shows PFS Benefit at 5-Year Follow-Up in BRCA Ovarian Cancer

September 18, 2020

Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.

MEK Inhibitor Binimetinib Shows Limited Activity in Low-Grade Serous Ovarian Carcinomas

September 14, 2020

Binimetinib demonstrated activity as treatment of patients with low-grade serous ovarian carcinomas in the randomized phase 3 MILO/ENGOT-ov11 study.